18F-2-fluoro-2-deoxy-D-glucose in Positron Emission Tomography Computed Tomography

Launched by EASTERN HEALTH, CANADA · Nov 2, 2020

Keywords

ClinConnect Summary

This clinical trial is studying a special imaging technique called Positron Emission Tomography Computed Tomography (PET/CT) that uses a substance called 18F-2-fluoro-2-deoxy-D-glucose (FDG). The goal is to see how safe this new version of FDG is for patients and to learn how well it can help doctors tell the difference between harmless and harmful lung nodules. This is particularly important for patients in Newfoundland and Labrador, who have faced delays in accessing this important test due to reliance on supplies from outside the province.

To participate in this trial, patients should have a known or suspected condition that the FDG PET/CT can help investigate, such as cancer, neurological disorders, or cardiac issues. Participants will need to provide consent and be in good enough health to complete the scan. It’s also important to note that pregnant women and those who cannot safely complete the scan due to medical reasons will not be eligible. If you decide to participate, you can expect to undergo a PET/CT scan, which will help improve local access to this important diagnostic tool for you and others in the community.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Known or suspected disease for which 18F-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography Computed Tomography is appropriate for the investigation of. This includes, but is not limited to: Known or suspected cancer, neurological disorders (dementia or epilepsy), cardiac conditions (inflammation or myocardial viability), known or suspected presence of infection/inflammation process
• Patients must satisfy all the following:
• • Able to provide written informed consent, or consent obtained from appropriate guardian
• • Able to tolerate the physical and logistic requirements of completing a Positron Emission Tomography Computed Tomography scan
• Exclusion Criteria:
• • Pregnant women: if there is any possibility of pregnancy, a blood Beta Human Chorionic Gonadotropin level will be obtained as per Eastern Health policy.
• • Patients unwilling or unable to stop breast feeding for 12 hours
• • Patients who are too medically unstable to tolerate the uptake period or lie flat for the duration of the scan
• • Patients who exceed the safe weight limit of the Positron Emission Tomography Computed Tomography scanner bed (500 lbs.) or who cannot fit through the bore (70 cm diameter)
• • Patients unwilling to proceed with scan (I.e. claustrophobia) prior to injection
• • If patients inability to follow staff direction causes a safety hazard prior to injection